AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)

/PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has submitted an application to the European Medicines Agency (EMA) seeking approval for risankizumab...

Related Keywords

,Gastroenterol Hepatol ,Tom Hudson ,Access Economics Pty ,Instagram ,Abbvie Ltd ,Linkedin ,Twitter ,Boehringer Ingelheim ,Exchange Commission ,European Union ,Value In Health ,Allergan ,European Medicines Agency ,Facebook ,Crohn Colitis Foundation Of America ,World Congress ,Safety Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Digestive Disease Week ,Virtual Conference ,European Gastroenterology Week Virtual ,Risankizumab Versus Treatment Withdrawal ,Year Double Blinded Results ,Rev Gastroenterol ,Inflammatory Bowel ,Colitis Foundation ,Global Diagnosed Prevalence ,Economic Costs ,Participants With Moderately ,Severely Active Crohn ,Disease Who Failed Prior Biologic ,Participants With Crohn ,Study Comparing Risankizumab ,Inadequate Response ,Biologic Therapy ,Placebo Controlled Induction Study ,Severely Active Ulcerative ,Abbvie ,